Detailed assessment of axial and peripheral entheses and joints in axial spondyloarthritis and psoriatic arthritis patients treated with ixekizumab – a 2-year study applying whole-body MRI, MRI-based synthetic CT, and CT

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510746-14-00

Enrollment

Registered

2024-04-05

Start date

2024-08-28

Completion date

Unknown

Last updated

2024-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis, Axial Spondyloarthritis

Brief summary

Change from baseline to month 12 in total inflammatory burden in the entire body (peripheral and axial joints and entheses), as assessed by WB-MRI, in patients with axSpA and PsA treated with IXE

Interventions

DRUGTaltz 80 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline to month 12 in total inflammatory burden in the entire body (peripheral and axial joints and entheses), as assessed by WB-MRI, in patients with axSpA and PsA treated with IXE	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026